Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal versus oral omeprazole in infants with GERD associated with esophageal atresia or congenital diaphragmatic hernia
NL-OMON38919Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of omeprazole in gastroesophageal reflux disease (GERD), sponsored by Erasmus MC. Primary endpoint: Treatment effectiveness. Started Dec 2013; status: active, not recruiting.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON38919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38919.